Neurocrine director receives 14,343 shares

NBIX director Kevin Gorman reported PRSU vesting and related tax-share withholding, with 517,797 shares held through a family trust after the transactions.

Available on EDGAR 09/15/2026 - 05:06 PM EDT Accepted by SEC EDGAR 09/15/2026 - 05:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC (NBIX) director Kevin Charles Gorman reported equity compensation activity on September 11, 2026. He acquired 14,343 shares of common stock at no cost upon vesting of previously granted performance restricted stock units after a performance metric was certified as achieved.

On the same date, 7,839 shares of common stock were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements related to the PRSU vesting at a reference price of $156.22 per share; no shares were sold into the market. Following these transactions, 517,797 outstanding shares are held by the Gorman and Blais Family Trust, over which Dr. Gorman has voting and investment power.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider GORMAN KEVIN CHARLES

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	14,343	$0.00	$0.00
Tax Withholding	Common Stock F2, F3	7,839	$156.22	$1.22M

Holdings After Transaction: Common Stock — 517,797 shares (Direct)

Footnotes (3)

1. F1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
2. F2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
3. F3. 517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Key Figures

Shares acquired via PRSU vesting: 14,343 shares Shares withheld for tax withholding requirements: 7,839 shares Tax withholding reference price: $156.22 per share +2 more

5 metrics

Shares acquired via PRSU vesting 14,343 shares Common stock credited to Kevin Gorman upon PRSU vesting on September 11, 2026

Shares withheld for tax withholding requirements 7,839 shares Common stock withheld by Neurocrine Biosciences, Inc. related to PRSU vesting on September 11, 2026

Tax withholding reference price $156.22 per share Price used for 7,839 shares withheld for tax obligations on September 11, 2026

Shares held by Gorman and Blais Family Trust 517,797 shares Outstanding NBIX shares held by the trust over which Dr. Gorman has voting and investment power

Transactions reported as tax-liability payment events 1 transaction One code F transaction for 7,839 shares withheld for tax withholding requirements

Key Terms

performance restricted stock units (PRSUs), tax withholding requirements, voting and investment power

3 terms

performance restricted stock units (PRSUs) financial

"The Reporting Person was previously granted performance restricted stock units (PRSUs)"

tax withholding requirements financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements"

voting and investment power financial

"of which Dr. Gorman has voting and investment power"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity transactions did NBIX director Kevin Gorman report on September 11, 2026?

He reported vesting of 14,343 performance restricted stock units into common shares at no cost and withholding of 7,839 shares by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements related to that vesting.

How many NBIX shares were acquired by Kevin Gorman through PRSU vesting?

On September 11, 2026, Kevin Gorman acquired 14,343 shares of NBIX common stock upon vesting of previously granted performance restricted stock units, following certification that a specified performance metric had been achieved.

Were any NBIX shares sold on the open market in this Form 4 filing?

No. The filing states that shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements on PRSU vesting and explicitly notes that no shares were sold.

What price per share was used for the NBIX tax withholding on Kevin Gorman’s vested shares?

For the tax withholding related to the PRSU vesting, 7,839 shares were withheld at a reference price of $156.22 per share, as disclosed in the transaction details.

How many NBIX shares does the Gorman and Blais Family Trust hold after these transactions?

After the reported transactions, 517,797 outstanding shares of NBIX common stock are held by the Gorman and Blais Family Trust, and the filing states that Dr. Gorman has voting and investment power over those shares.

Were Kevin Gorman’s NBIX transactions made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that the Rule 10b5-1 checkbox is not marked, and there is no footnote indicating that these transactions were executed pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GORMAN KEVIN CHARLES

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A(1)		14,343	A	$0	525,636	D
Common Stock	09/11/2026		F(2)		7,839	D	$156.22	517,797(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

3. 517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)